Track topics on Twitter Track topics that are important to you
WASHINGTON — PCSK9 inhibition with bococizumab was safe in high-risk patients with LDL levels exceeding 100 mg/dL, but yielded mixed results on efficacy due to attenuation of LDL lowering, variation in individual response, antidrug antibody production and early termination of drug development.At the American College of Cardiology Scientific Session, Paul M. Ridker, MD, Eugene Braunwald professor of medicine at Harvard Medical School and director of the Center for Cardiovascular Disease Prevention, reported data from eight parallel bococizumab trials in the SPIRE clinical trial program. The SPIRE-1 and SPIRE-2 CV outcome trials were halted early in November when Pfizer made the decision to discontinue development of bococizumab after high rates of antidrug antibodies and unanticipated attenuation of LDL lowering over time were observed in six lipid-lowering studies.
Original Article: Bococizumab yields varying effects on CV events, LDL in SPIRE trialsNEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...